FUSCC criteria for the management of targeted drug-induced interstitial lung disease in solid tumors

张　剑; 沈维娜; 季冬梅; 王磊苹; 龚成成; 胡夕春

doi:10.19401/j.cnki.1007-3639.2021.04.001

您当前的位置：

首页 >

文章列表页 >

FUSCC criteria for the management of targeted drug-induced interstitial lung disease in solid tumors

更新时间：2026-01-27

- FUSCC criteria for the management of targeted drug-induced interstitial lung disease in solid tumors
- China Oncology Vol. 31, Issue 4, Pages: 241-249(2021)
- 作者机构：
  
  1. 复旦大学附属肿瘤医院肿瘤内科，复旦大学上海医学院肿瘤学系,上海,200032
  2. 上海市抗癌协会肿瘤药物临床研究专业委员会,上海,200032
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2021.04.001
  CLC： R730.5
- Published Online：28 April 2021，
  
  Published：28 April 2021
- 稿件说明：
移动端阅览
张　剑, 沈维娜, 季冬梅, 王磊苹, 龚成成, 胡夕春 . 实体瘤中靶向药所致间质性肺病管理的复旦大学附属肿瘤医院标准[J]. 中国癌症杂志, 2021, 31(4): 241-249.

张　剑, 沈维娜, 季冬梅, et al. FUSCC criteria for the management of targeted drug-induced interstitial lung disease in solid tumors[J]. China Oncology, 2021, 31(4): 241-249.
张　剑, 沈维娜, 季冬梅, 王磊苹, 龚成成, 胡夕春 . 实体瘤中靶向药所致间质性肺病管理的复旦大学附属肿瘤医院标准[J]. 中国癌症杂志, 2021, 31(4): 241-249. DOI： 10.19401/j.cnki.1007-3639.2021.04.001.

张　剑, 沈维娜, 季冬梅, et al. FUSCC criteria for the management of targeted drug-induced interstitial lung disease in solid tumors[J]. China Oncology, 2021, 31(4): 241-249. DOI： 10.19401/j.cnki.1007-3639.2021.04.001.

摘要

药物所致间质性肺病（drug-induced interstitial lung disease，DILD）受到越来越多的关注，尤其是针对靶向药物和新一代抗体药物偶联物（antibody-drug conjugate，ADC）。DILD是一种常见的肺毒性疾病，对患者往往有致命性，因此需要早发现、早干预。无症状或无特异性症状使DILD诊断困难，故应在临床实践中定期进行CT检查。在DILD的早期采用“实体瘤中靶向药所致间质性肺病管理的复旦大学附属肿瘤医院标准”治疗，有望逆转这种药物相关的毒性及不良预后。

Abstract

Drug-induced interstitial lung disease (DILD) has already been paid more and more attention

especially for targeted agents and newer generation antibody-drug conjugates (ADC). DILD is a common pulmonary toxicity and may be lethal to the patients

requiring early diagnosis and intervention. No symptom or no specific symptoms make the diagnosis difficult

and periodic CT monitoring should be performed in the clinical practice. Early use of Fudan University Shanghai Cancer Center criteria for management of targeted drug-induced interstitial lung disease in solid tumors can reverse the poor prognosis of this drug-related toxicity.

关键词

Keywords

references

Views

5177

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Phase Ⅰ study of intrathecal pemetrexed combined with programmed death-1 inhibitor for leptomeningeal metastases from solid tumors

TCR-T immunotherapy for the treatment of solid tumor: current status, challenges and future prospects

Related Author

Miaomiao LIU

Yushan HUANG

Guozi YANG

Panpan TAI

Xiao CHEN

Min LIU

Zhenyu PAN

Weitao ZHENG

Related Institution

Department of Radiation Oncology, Affiliated Huizhou Hospital of Guangzhou Medical University/Third People’s Hospital of Huizhou City

Sino-German Biomedical Center, National “111” Center for Cellular Regulation and Molecular Pharmaceutics, Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), Hubei University of Technology

AI问答

⁰